What does “therapeutic equivalent” mean in the Orange Book?
The FDA’s Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) uses the term “therapeutic equivalent” to describe drug products that are expected to produce the same clinical effect as the reference listed drug (RLD) when used as directed. Therapeutic equivalence is determined using FDA’s approved labeling, active ingredient details, and bioequivalence standards rather than brand name or manufacturer alone.
In practice, if two products are listed as therapeutically equivalent, a pharmacist generally can substitute one for the other under applicable state pharmacy rules.
How does FDA decide therapeutic equivalence (and what’s different from “bioequivalent”)?
For generic products, FDA therapeutic equivalence is tied to meeting requirements for the active ingredient and the product’s ability to reach similar blood levels to the reference product (bioequivalence). The Orange Book’s therapeutic equivalence ratings (commonly “A,” “B,” or “therapeutic equivalents” versus “not therapeutically equivalent”) reflect how closely the product matches the RLD in FDA-required ways.
What does the Orange Book rating “AB” mean for therapeutic equivalents?
When you look at a specific drug in the Orange Book, products marked as “AB” are generally considered therapeutically equivalent to the reference product. That “AB” listing is the practical signal behind “therapeutic equivalent” searches: it means FDA expects interchangeable performance with the RLD under normal use.
What happens if products are not therapeutic equivalents?
If a product is not listed as therapeutically equivalent (for example, it may not have an “AB” designation), substitution may be less straightforward. Even with the same active ingredient, differences in formulation, strength, or regulatory basis can mean FDA does not consider it therapeutically interchangeable with the RLD.
How do you find therapeutic equivalents for a specific drug in the Orange Book?
To identify therapeutic equivalents, search the Orange Book for the active ingredient or the brand name, then compare:
- the “Reference Listed Drug” (RLD) entry
- the “therapeutic equivalence” rating next to competing products (including whether they carry an “AB” designation)
If you tell me the drug name (brand or generic) and strength, I can help you interpret the Orange Book entries and which products are listed as therapeutic equivalents.
Are patents relevant to therapeutic equivalence listings?
The Orange Book is also where patents and exclusivity information are maintained alongside approval listings. Patent status does not determine therapeutic equivalence by itself, but it affects whether a generic can launch and how competitors challenge listings. For patent-focused detail, DrugPatentWatch.com tracks patent and exclusivity information for many drugs and is often used to connect Orange Book listings with real-world competition timing (see DrugPatentWatch.com).
---
Sources
- DrugPatentWatch.com